1. Home
  2. BRIA vs ALGS Comparison

BRIA vs ALGS Comparison

Compare BRIA & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BRIA
  • ALGS
  • Stock Information
  • Founded
  • BRIA 2011
  • ALGS 2018
  • Country
  • BRIA Singapore
  • ALGS United States
  • Employees
  • BRIA N/A
  • ALGS N/A
  • Industry
  • BRIA
  • ALGS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BRIA
  • ALGS Health Care
  • Exchange
  • BRIA NYSE
  • ALGS Nasdaq
  • Market Cap
  • BRIA 62.0M
  • ALGS 50.4M
  • IPO Year
  • BRIA 2024
  • ALGS 2020
  • Fundamental
  • Price
  • BRIA $2.38
  • ALGS $8.46
  • Analyst Decision
  • BRIA
  • ALGS Strong Buy
  • Analyst Count
  • BRIA 0
  • ALGS 1
  • Target Price
  • BRIA N/A
  • ALGS $70.00
  • AVG Volume (30 Days)
  • BRIA 2.8K
  • ALGS 99.2K
  • Earning Date
  • BRIA 08-15-2025
  • ALGS 08-05-2025
  • Dividend Yield
  • BRIA N/A
  • ALGS N/A
  • EPS Growth
  • BRIA N/A
  • ALGS N/A
  • EPS
  • BRIA 92.24
  • ALGS N/A
  • Revenue
  • BRIA $59,695,825.00
  • ALGS $3,270,000.00
  • Revenue This Year
  • BRIA N/A
  • ALGS N/A
  • Revenue Next Year
  • BRIA N/A
  • ALGS $51.55
  • P/E Ratio
  • BRIA $0.03
  • ALGS N/A
  • Revenue Growth
  • BRIA 8.03
  • ALGS N/A
  • 52 Week Low
  • BRIA $1.78
  • ALGS $3.76
  • 52 Week High
  • BRIA $4.38
  • ALGS $46.80
  • Technical
  • Relative Strength Index (RSI)
  • BRIA N/A
  • ALGS 63.36
  • Support Level
  • BRIA N/A
  • ALGS $6.82
  • Resistance Level
  • BRIA N/A
  • ALGS $9.10
  • Average True Range (ATR)
  • BRIA 0.00
  • ALGS 0.75
  • MACD
  • BRIA 0.00
  • ALGS 0.08
  • Stochastic Oscillator
  • BRIA 0.00
  • ALGS 86.38

About BRIA BRILLIA INC

BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.

About ALGS Aligos Therapeutics Inc.

Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Share on Social Networks: